Clinical evaluation of C4X3256, a non-opioid, highly-selective orexin-1 receptor antagonist for the treatment of opioid use disorder
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG3DA050308
- Recipient
-
Indivior Inc. UEI VLCNBHCXCCJ9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,779,849
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Bon Air, VA 23235, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $2,763,621 | |
| Amendment | $0 | |
| Original award | $3,016,228 |
Quick answers
Who received award UG3DA050308?
UG3DA050308 was awarded to Indivior Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2019.
How much is award UG3DA050308 worth?
$5,779,849 has been obligated on UG3DA050308.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award